BC Extra | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy  Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive rights to develop and commercialize tapinarof in Japan for dermatology indications including psoriasis and atopic dermatitis. The...
BC Week In Review | Jul 12, 2019
Company News

First domestic company gets a first-in-class approval in China

China's National Medical Products Administration (NMPA) approved in May an NDA from Beijing Wenfeng Tianji Pharmaceuticals Co. Ltd. (Beijing, China) for tapinarof (DMVT-505, WBI-1001, benvitimod) to treat mild to moderate stable psoriasis vulgaris. The product...
BC Extra | May 25, 2019
Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
BC Week In Review | Aug 31, 2018
Company News

Dermavant, NovaQuest in milestone deal for tapinarof

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) received the $100 million investment from NovaQuest Capital Management in exchange for milestone payments related to tapinarof. The aryl hydrocarbon receptor (AHR) modulator has...
BC Week In Review | Jul 13, 2018
Company News

Dermatitis, psoriasis candidate passed from GSK to Dermavant

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) will shell out £150 million ($200 million) up front to GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to receive global rights to atopic dermatitis and psoriasis candidate...
BC Extra | Jul 12, 2018
Company News

GSK hands off dermatitis, psoriasis candidate to Dermavant

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) will shell out £150 million ($200 million) up front to GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to receive global rights to atopic dermatitis and psoriasis candidate...
BC Week In Review | Jun 4, 2012
Company News

Welichem Biotech, GlaxoSmithKline deal

Welichem granted GlaxoSmithKline's Stiefel Laboratories Inc. subsidiary exclusive rights outside of China, Taiwan, Macau and Hong Kong to develop and commercialize WBI-1001 . The product is a topical non-steroidal and non-immunosuppressive agent in Phase II testing...
Items per page:
1 - 7 of 7